Extension of HLA-A*0201-restricted minimal epitope by N(ε)-palmitoyl- lysine increases the life span of functional presentation to cytotoxic T cells

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 900-907

  Loing, Estelle ^a,d   Andrieu, Muriel ^b   Thiam, Kader ^a   Schörner, Dominik ^c   Wiesmüller, Karl Heinz ^c   Hosmalin, Anne ^b   Jung, Günther ^c   Gras Masse, Hélène ^a  

^a CNRS   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; LYSINE DERIVATIVE; ABC TRANSPORTER; DRUG DERIVATIVE; FLUORESCENT DYE; LIPOPROTEIN; LYSINE; N(EPSILON) PALMITOYLLYSINE; N(EPSILON)-PALMITOYLLYSINE; PEPTIDE; RHODAMINE; TAP1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; AMINO ACID SUBSTITUTION; CELL LINE; CELL SURVIVAL; CYTOLOGY; GENETICS; HYBRID CELL; IMMUNOLOGY; KINETICS; MACROMOLECULE; METABOLISM;

AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TRANSFORMED; CELL SURVIVAL; EPITOPES, T-LYMPHOCYTE; FLUORESCENT DYES; HLA-A ANTIGENS; HUMANS; HYBRID CELLS; KINETICS; LIPOPROTEINS; LYSINE; MACROMOLECULAR SUBSTANCES; PEPTIDES; RHODAMINES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034649784     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.900     Document Type: Article

References (51)

1. Rock, K. L. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131.
2. Heemels, M. T., and H. L. Ploegh. 1994. Substrate specificity of allelic variants of the TAP peptide transporter. Immunity 7:775.
3. Shepherd, J. C., T. N. Schumacher, P. G. Ashton-Rickardt, S. Imaeda, H. L. Ploegh, C. A. Janeway, and S. Tonegawa. Jr. 1993. TAP I-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 74:577.
4. Srivastava, P. K., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93.
5. Nieland, T. J., M. C. Tan, M. Monne van Muijen, F. Koning, A. M. Kruisbeek, and G. M. van Bleek. 1996. Isolation of an imrminodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc. Natl. Acad. Sci. USA 91:6135.
6. Nicchita, C. 1998. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr. Opin. Immunol. 10:103.
7. Chen, W., S. Khilko, J. Fecondo, D. H. Margulies, and J. McCluskey. 1994. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180:1471.
8. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff. L. Yuan, J. Ruppert, J. Sidney, M. F. del Guercio, S. Southwood, R. T. Kubo, R. W. Chesnut, H. M. Grey, and F. V. Chisari. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
9. Kast, W. M., R. M. Brandt, J. Sidney, J. W. Drijfhout, R. T. Kubo, H. M. Grey, C. J. Melief, and A. Sette. 1994. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152:3904.
10. van der Burg, S. H., M. J. Visseren, R. M. Brandt, W. M. Kast, and C. J. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308.
11. Levitsky, V., Q. J. Zhang, J. Levitskaya, and M. G. Masucci. 1996. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J. Exp. Med. 183: 915.
12. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89.
13. + CTL clones is determined by the frequency of serial TCR engagement. J. Immunol. 161:553.
14. Townsend, A. R., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959.
15. Wiesmüller, K.-H., M. Brich, G. Jung, K. Sparbier, and P. Walden. 1995. Peptide binding to MHC class I molecules analysed by confocal microscopy. Eur. J. Cell Biol. 66:389.
16. Niedermann, G., S. Butz, H. G. Ihlenfeldt, R. Grimm, M. Lucchiari, H. Hoschutzky, G. Jung, B. Maier, and K. Eichmann. 1995. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2:289.
17. Mamula, M. J. 1993. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J. Exp. Med. 177:567.
18. Dick, L. R., C. Aldrich, S. C. Jameson, C. R. Moomaw, B. C. Pramanik, C. K. Doyle, G. N. DeMartino, M. J. Bevan, J. M. Forman, and C. A. Slaughter. 1994. Proteolytic processing of ovalbunim and β-galactosidase by the proteasome to a yield antigenic peptides. J. Immunol. 152:3884.
19. Deres, K., H. Schild, K.-H. Wiesmüller, G. Jung, and H. G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561.
20. Martinon, F., H. Gras-Masse, C. Boutillon, E. Gomard, B. Deprez, A. Tartar, and J.-P. Levy. 1992. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant : immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:3416.
21. Bourgault-Villada, I., L. Mortara, A. M. Aubertin, H. Gras-Masse, J.-P. Levy, and J. G. Guillet. 1997. Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period. FEMS Immunol. Med. Microbiol. 19:81.
22. Livingston, B. D., C. Crimi, H. Grey, G. Ishioka, F. V. Chisari, J. Fikes, H. Grey, R. W. Chesnut, and A. Sette. 1997. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1383.
23. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:341.
24. Oseroff, C., A. Sette, P. Wentworth, E. Celis, A. Maewal, C. Dahlberg, J. Fikes, R. T. Kubo, R. W. Chesnut, H. M. Grey, and J. Alexander. 1998. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine 16:823.
25. Loing, E., A. Delanoye, C. Sergheraert, A. Tartar, and H. Gras-Masse. 1996. Assessing delivery of lipopeptide into the cytoplasm of intact cells by a functional assay based on PKC inhibition. 1. The Jurkat model. Pept. Res. 9:229.
26. Loing, E., K. Thiam, K., F. Gilles, C. Verwaerde, B. Quatannens, C. Auriault, and H. Gras-Masse. 1997. Induction of apoptosis by protein kinase C pseudosubstrate lipopeptides in several human cells. Lett. Pept. Sci. 4:397.
27. Thiam, K., E. Loing, A. Delanoye, E. Diesis, H. Gras-Masse, C. Auriault, and C. Verwaerde. 1998. Unrestricted agonist activity on murine and human cells of a lipopeptide derived from IFN-γ. Biochem. Biophys. Res. Commun. 253:639.
28. Thiam, K., E. Loing, C. Verwaerde, C. Auriault, and H. Gras-Masse. 1999. IFN-γ-derived lipopeptides: influence of lipid modification on the conformation and the ability to induce MHC class II expression in murine and human cells. J. Med. Chem. 42:3732.
29. Stephens, G., N. O'Luanaigh, D. Reilly, P. Harriott, B. Walker, D. Fitzgerald, and N. Moran. 1998. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J. Biol. Chem. 273: 20317.
30. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276.
31. Madden, D. R., D. N. Garboczi, and D. C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693.
32. Madden, D. R. 1995. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13:587.
33. Pogue, R. R., J. Eron, J. A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*0201 -restricted human immunodeficiency virus pol peptide increases complex stability and in vivo immunogenicity. Proc. Natl. Acad. Sci. USA 92:8166.
34. Fields, G. B., and R. L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxy carbonyl amino acids. Int. J. Pept. Prot. Res. 35:161.
35. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class 1 antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235.
36. + cells in the central region of the HIV-1 Nef protein. J. Immunol. 146:1560.
37. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:221.
38. Hudrisier, D., and J. E. Gairin. 1998. Peptide-major histocompatibility complex class I complex: from the structural and molecular basis to pharmacological principles and therapeutic applications. Curr. Top. Microbiol. Immunol. 232:75.
39. Parham, P., and F. Brodsky. 1981. Partial purification and some properties of BB7.2. Hum. Immunol. 3:277.
40. Misumi, Y , Y. Misumi, K. Miki, A. Takatsuki, G. Tamura, and Y. Ikehara. 1986. Novel blockage by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J. Biol. Chem. 261:11398.
41. Abdel Motal, U. M., X. Zhou, A. Joki, A. R. Siddiqi, B. R. Srinivasa, K. Stenvall, J. Dahmén, and M. Jondal. 1993. Major histocompatibility complex class I-binding peptides are recycled to the cell surface after internalization. Eur. J. Immunol. 23:3224.
42. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45.
43. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. N. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
44. Toes, R. E., E. I. van der Voort, S. P. Schoenherger, J. W. Drijfhout, L. van Bloois, G. Storm, W. M. Kast, R. Offringa, and C. J. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:4449.
45. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242.
46. Mortara, L., F. Letourneur, H. Gras-Masse, A. Venet, J. G. Guillet, and I. Bourgault-Villada. 1998. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72:1403.
47. Klinguer, C., D. David, M. Kouach, J. M. Wieruszeski, A. Tartar, D. Marzin, J.-P. Levy, and H. Gras-Masse. 1999. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vairine 18:259.
48. Diamond. D. J., J. York, J. Y. Sun, C. L. Wright, and S. J. Forman. 1997. Development of a candidate HLA-A*0201 restricted pepude-based vaccine against human cytomegalovirus infection. Blood 90:1751.
49. Loing, E., K. Thiam, D. Zoukhri, C. Rommens, R. Hodges, D. Dam, C. Verwaerde, C. Auriault, H. Gras-Masse, and C. Sergheraert. 1999. Direct evidence of cytoplasmic delivery of PKC-α, -ε and -ζ pseudosubstrate lipopeptides: study of their implication in the induction of apoptosis. FEBS Lett. 459:285.
50. + T cells in vivo. Proc. Natl. Acad. Sci. USA 91:3077.
51. Wiesmüller, K.-H., K. Deres, H. Schild, H. G. Rammensee, and G. Jung. 1990. Minimal structure of lipopeptides for in vivo priming of cytotoxic T-lymphocytes. In Peptides. E. Giralt and D. Andreu, eds. ESCOM. Leiden, The Netherlands, p. 857.